The NADPH oxidase inhibitor imipramine-blue in the treatment of burkitt lymphoma

Molecular Cancer Therapeutics

Volumn 13, Issue 4, 2014, Pages 833-841

  Klingenberg, Marcel ^a   Becker, Jürgen ^a   Eberth, Sonja ^a   Kube, Dieter ^a   Wilting, Jörg ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CRYSTAL VIOLET; DOXORUBICIN; IMIPRAMINE BLUE; UNCLASSIFIED DRUG; IMIPRAMINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANGIOSARCOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BURKITT LYMPHOMA; CANCER CELL; CANCER CELL CULTURE; CELL VIABILITY; CHICK; CHORIOALLANTOIS; CONTROLLED STUDY; EMBRYO; HELA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; INOCULATION; LYMPH VESSEL; LYMPHOMA CELL; MTT ASSAY; NEUROBLASTOMA CELL; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT; UTERINE CERVIX CARCINOMA; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CELL SURVIVAL; CHICK EMBRYO; DRUG EFFECTS; DRUG SCREENING; EXPERIMENTAL NEOPLASM; HEK293 CELL LINE; HELA CELL LINE; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BURKITT LYMPHOMA; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; HEK293 CELLS; HELA CELLS; HUMANS; IMIPRAMINE; NADPH OXIDASE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84921312097     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-13-0688     Document Type: Article

References (41)

1. Munson JM, Fried L, Rowson SA, Bonner MY, Karumbaiah L, Diaz B, et al. Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci Transl Med 2012;4:127ra36.
2. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006;107:265-76.
3. Molyneux EM, Rochford R, Griffin B, Newton R, Jackson G, Menon G, et al. Burkitt's lymphoma. Lancet 2012;379:1234-44.
4. Kaiser U, Uebelacker I, Abel U, Birkmann J, Trümper L, Schmalenberg H, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 2002;20:4413-9.
5. Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, Bittner S, et al. Practicability and acute haematological toxicity of 2- and 3- weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High- Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol Off J Eur Soc Med Oncol ESMO 2003;14:881-93.
6. Aldoss IT, Weisenburger DD, Fu K, Chan WC, Vose JM, Bierman PJ, et al. Adult Burkitt lymphoma: advances in diagnosis and treatment. Oncol Williston Park N 2008;22:1508-17.
7. Pui C-H, Thiel E. Central nervous system disease in hematologic malignancies: historical perspective and practical applications. Semin Oncol 2009;36:S2-16.
8. Wästerlid T, Brown PN, Hagberg O, Hagberg H, Pedersen LM, D'Amore F, et al. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol Off J Eur Soc Med Oncol ESMO 2013;24:1879-86.
9. Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol Off J Eur Soc Med Oncol ESMO 2011;22:1859-64.
10. Wondrak GT. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 2009;11:3013-69.
11. Trachootham D, Lu W, Ogasawara MA, Nilsa R-DV, Huang P. Redox regulation of cell survival. Antioxid Redox Signal 2008;10:1343-74.
12. Ray PD, Huang B-W, Tsuji Y. Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling. Cell Signal 2012;24:981-90.
13. Gupta SC, Hevia D, Patchva S, Park B, Koh W, Aggarwal BB. Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal 2012;16:1295-322.
14. Shi J-M, Bai L-L, Zhang D-M, Yiu A, Yin Z-Q, Han W-L, et al. Saxifragifolin D induces the interplay between apoptosis and autophagy in breast cancer cells through ROS-dependent endoplasmic reticulum stress. Biochem Pharmacol 2013;85:913-26.
15. Vaquero EC, Edderkaoui M, Pandol SJ, Gukovsky I, Gukovskaya AS. Reactive oxygen species produced by NAD(P)H oxidase inhibit apoptosis in pancreatic cancer cells. J Biol Chem 2004;279:34643-54.
16. Szatrowski TP, Nathan CF. Production of large amounts of hydrogen peroxide by human tumor cells. Cancer Res 1991;51:794-8.
17. Park HS, Jung HY, Park EY, Kim J, Lee WJ, Bae YS. Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-κB. J Immunol Baltimore, MD 1950. 2004;173:3589-93.
18. Hussain AR, Ahmed SO, Ahmed M, Khan OS, Al Abdulmohsen S, Platanias LC, et al. Cross-talk between NF-κB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One 2012;7:e39945.
19. Mochizuki T, Furuta S, Mitsushita J, Shang WH, Ito M, Yokoo Y, et al. Inhibition of NADPH oxidase 4 activates apoptosis via the AKT/apoptosis signal-regulating kinase 1 pathway in pancreatic cancer PANC- 1 cells. Oncogene 2006;25:3699-707.
20. Becker J, Covelo-Fernandez A, von Bonin F, Kube D, Wilting J. Specific tumor-stroma interactions of EBV-positive Burkitt's lymphoma cells in the chick chorioallantoic membrane. Vasc Cell 2012;4:3.
21. Cerimele F, Battle T, Lynch R, Frank DA, Murad E, Cohen C, et al. Reactive oxygen signaling and MAPK activation distinguish Epstein- Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A 2005;102:175-9.
22. Bertrand S, Berger R, Philip T, Bernheim A, Bryon PA, Bertoglio J, et al. Variant translocation in a non endemic case of Burkitt's lymphoma: t (8;22) in an Epstein-Barr virus negative tumour and in a derived cell line. Eur J Cancer 1981;17:577-84.
23. Munson JM, Bellamkonda RV, Swartz MA. Interstitial flow in a 3D microenvironment increases glioma invasion by a CXCR4-dependent mechanism. Cancer Res 2013;73:1536-46.
24. Sevimli-Gur C, Akgun IH, Deliloglu-Gurhan I, Korkmaz KS, Bedir E. Cytotoxic naphthoquinones from Alkanna cappadocica (perpendicular). J Nat Prod 2010;73:860-4.
25. La Regina G, Bai R, Rensen W, Coluccia A, Piscitelli F, Gatti V, et al. Design and synthesis of 2-heterocyclyl-3-arylthio-1H-indoles as potent tubulin polymerization and cell growth inhibitors with improved metabolic stability. J Med Chem 2011;54:8394-406.
26. Gomez-Monterrey I, Bertamino A, Porta A, Carotenuto A, Musella S, Aquino C, et al. Identification of the Spiro(oxindole-3,30-thiazolidine)- based derivatives as potential p53 activity modulators. J Med Chem 2010;53:8319-29.
27. Carvalho JFS, Silva MMC, Moreira JN, Simoes S, Sá E, Melo ML. Selective cytotoxicity of oxysterols through structural modulation on rings A and B. Synthesis, in vitro evaluation, and SAR. J Med Chem 2011;54:6375-93.
28. Afanasyeva EA, Mestdagh P, Kumps C, Vandesompele J, Ehemann V, Theissen J, et al. MicroRNA miR-885-5p targets CDK2 and MCM5, activates p53 and inhibits proliferation and survival. Cell Death Differ 2011;18:974-84.
29. Fried L, Arbiser JL. The reactive oxygen-driven tumor: relevance to melanoma. Pigment Cell Melanoma Res 2008;21:117-22.
30. Bonner MY, Arbiser JL. Targeting NADPH oxidases for the treatment of cancer and inflammation. Cell Mol Life Sci CMLS 2012;69:2435-42.
31. Becker J, Erdlenbruch B, Noskova I, Schramm A, Aumailley M, Schorderet DF, et al. KERatoepithelin suppresses the progression of experimental human neuroblastomas. Cancer Res 2006;66:5314-21.
32. Brodeur GM, Seeger RC, Barrett A, Berthold F, Castleberry RP, D'Angio G, et al. International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma. J Clin Oncol Off J Am Soc Clin Oncol 1988;6:1874-81.
33. Shibata M-A, Ambati J, Shibata E, Albuquerque RJC, Morimoto J, Ito Y, et al. The endogenous soluble VEGF receptor-2 isoform suppresses lymph node metastasis in a mouse immunocompetent mammary cancer model. BMC Med 2010;8:69.
34. Tagawa H, Karnan S, Kasugai Y, Tuzuki S, Suzuki R, Hosokawa Y, et al. MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8. Oncogene 2004;23:2576-81.
35. Chang G, Chen L, Lin H-M, Lin Y, Maranchie JK. Nox4 inhibition enhances the cytotoxicity of cisplatin in human renal cancer cells. J Exp Ther Oncol 2012;10:9-18.
36. Dong J-M, Zhao S-G, Huang G-Y, Liu Q. NADPH oxidase-mediated generation of reactive oxygen species is critically required for survival of undifferentiated human promyelocytic leukemia cell line HL-60. Free Radic Res 2004;38:629-37.
37. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol Off J Am Soc Clin Oncol 2002;20:125-33.
38. Pierre A-S, Minville-Walz M, Févre C, Hichami A, Gresti J, Pichon L, et al. Trans-10, cis-12 conjugated linoleic acid induced cell death in human colon cancer cells through reactive oxygen species-mediated ER stress. Biochim Biophys Acta 2013;1831:759-68.
39. Rasul A, Bao R, Malhi M, Zhao B, Tsuji I, Li J, et al. Induction of apoptosis by costunolide in bladder cancer cells is mediated through ROS generation and mitochondrial dysfunction. Mol Basel Switz 2013;18:1418-33.
40. Lin TS, Naumovski L, Lecane PS, Lucas MS, Moran ME, Cheney C, et al. Effects of motexafin gadolinium in a phase II trial in refractory chronic lymphocytic leukemia. Leuk Lymphoma 2009;50:1977-82.
41. Ma B, Goh BC, Tan EH, Lam KC, Soo R, Leong SS, et al. A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells. Invest New Drugs 2008;26:169-73.